Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 umbrella study of investigational agents with Keytruda with or without chemotherapy in advanced non-small cell lung cancer
MOH_2020-09-14_009132Phase 2Recruiting
- Sponsor
- Merck & Co.
- Start
- Sep 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of pembrolizumab in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Merck & Co. Started Sep 2020; status: recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on MOH_2020-09-14_009132.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-09-14_009132.